Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23516515 | 0.96 | METAP2 (0.43) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23515971 | 0.91 | CYP11B1 (0.45) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23516508 | 0.89 | CYP11B2 (0.43) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23516094 | 0.88 | METAP2 (0.43) | METAP2CHEK1CAPN1 | |
| SCHEMBL23516485 | 0.86 | ALDH1A1 (0.46) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23516229 | 0.85 | HTT (0.45) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23516356 | 0.84 | MAPK14 (0.41) | METAP2CHEK1MAPK14 | |
| SCHEMBL23515988 | 0.84 | MEN1 (0.36) | MAPK14 | |
| SCHEMBL23516272 | 0.84 | PDE6D (0.42) | METAP2CYP11B1CYP11B2CHEK1CYP19A1 | |
| SCHEMBL23515970 | 0.82 | MAPK14 (0.42) | CYP11B1CYP11B2CYP19A1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11276825-B2 | Organic molecules for use in organic devices | CYNORA GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | CHRM1, C1S, DNMT3L | METAP2 3053/4885CYP11B1 386/4885CYP11B2 740/4885 |
| US-11276825-B2 | Organic molecules for use in organic devices | AOX1, OR10J3, L1CAM | METAP2 3608/4885CYP11B1 557/4885CYP11B2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.